Crowning the New King of Biotech

This episode of The Motley Fool's Market Checkup is dedicated to the world's largest pure-play biotech stock, Gilead Sciences . Market Checkup gives a full examination of Gilead's second-quarter results, takes a closer look at the company's current product portfolio, and analyzes the future drugs that have investors excited about the stock's future.

In this video, health-care analysts David Williamson and Max Macaluso drill down on Gilead's strong second-quarter results. Watch and find out why Gilead's performed so well lately, and which drugs drove quarterly results higher.

It's no secret that biotech stocks have been soaring recently, but the best investment strategy is to pick great companies and stick with them for the long term. The Motley Fool's free report, "3 Stocks That Will Help You Retire Rich," not only shares stocks that could help you build long-term wealth, but also winning strategies that every investor should know. Click here to grab your free copy today.

Follow David on Twitter: @MotleyDavid.

The article Crowning the New King of Biotech originally appeared on Fool.com.

David Williamson owns shares of Eli Lilly. Follow David on Twitter: @MotleyDavid. Max Macaluso, Ph.D. owns shares of Gilead Sciences. The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.